Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England.
Smith, James Nicholas
MetadataShow full item record
Wilkinson, A. J., Braggins, R., Steinbach, I., & Smith, J. N. (2019). Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England.. BMJ open, 9 (10), e028763. https://doi.org/10.1136/bmjopen-2018-028763
Objectives: Metered dose inhalers (MDIs) contain propellants which are potent greenhouse gases. Many agencies propose a switch to alternative, low global warming potential (GWP) inhalers, such as dry powder inhalers (DPIs). We aimed to analyse the impact on greenhouse gas emissions and drug costs of making this switch. Setting: We studied NHS prescription data from England in 2017 and collated carbon footprint data on inhalers commonly used in England. Design: Inhalers were separated into different categories according to their mechanisms of action (e.g. short-acting beta agonist). Within each category we identified low and high GWP inhalers and calculated the cost and carbon impact of changing to low-GWP inhalers. We modelled scenarios for swapping proportionally according to the current market share of each equivalent DPI (model 1) and switching to the lowest cost pharmaceutically equivalent DPI (model 2). We also reviewed available data on the carbon footprint of inhalers from scientific publications, independently certified reports and patents to provide more accurate carbon footprint information on different types of inhalers. Results: If MDIs using HFA propellant are replaced with the cheapest equivalent DPI, then for every 10% of MDIs changed to DPIs, drug costs decrease by £8.2M annually. However if the brands of DPIs stay the same as 2017 prescribing patterns, for every 10% of MDIs changed to DPIs, drug costs increase by £12.7M annually. Most potential savings are due to less expensive LABA/ICS inhalers. Some reliever inhalers (e.g. Ventolin™) have a carbon footprint over 25kgCO2e per inhaler, whilst others use far less HFA134a (e.g. Salamol™) with a carbon footprint of less than 10kgCO2e per inhaler. HFA227ea LABA/ICS inhalers (e.g. Flutiform™) have a carbon footprint over 36kgCO2e, compared to an equivalent HFA134a combination inhaler (e.g. Fostair™) at less than 20kgCO2e. For every 10% of MDIs changed to DPIs, 58ktCO2e could be saved annually in England. Conclusions: Switching to DPIs would result in large carbon savings and can be achieved alongside reduced drug costs by using less expensive brands. Substantial carbon savings can be made by using small volume HFA134a MDIs, in preference to large volume HFA134a MDIs, or those containing HFA227ea as a propellant.
Humans, Metered Dose Inhalers, Drug Costs, State Medicine, England, Global Warming, Carbon Footprint, Dry Powder Inhalers, Greenhouse Gases
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors’
Embargo Lift Date
External DOI: https://doi.org/10.1136/bmjopen-2018-028763
This record's URL: https://www.repository.cam.ac.uk/handle/1810/297582
Attribution-NonCommercial 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc/4.0/